Eisai100 Tice Blvd.
Woodcliff Lake, NJ 07677
Eisai Inc. and Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has extended the action date for the supplemental New Drug Application (sNDA) for lenvatinib for the potential first-line treatment of patients with unresectable hepatocellular carcinoma (HCC). Read More »
Eisai Inc.'s supplemental New Drug Application for Fycompa CIII has been accepted by the U.S. Food and Drug Administration. Read More »
Eisai Inc. last week announced that new data on FYCOMPA (perampanel) CIII presented at the 12th European Congress on Epileptology (ECE) has shown that adjunctive use of the medication for up to two-and-a-half years has proven to deliver persistent seizure control in patients suffering from primary generalized tonic clonic (PGTC) seizures who have been poorly controlled. Read More »
FYCOMPA is now available as an oral suspension for patients who cannot take tablets. Read More »
Eisai Co. Ltd. and Ajinomoto Co. Inc. have announced the establishment of EA Pharma Co. Ltd., based on the integration agreement signed by both companies on October 15 of last year. Read More »
Eisai Co. and Sysmex Corp. made a joint announcement this week declaring that the two companies have agreed on a non-exclusive partnership to develop new diagnostics for the field of dementia. Read More »